Drug Trial Radar · NCT06911567
A Study to Assess New Formulations of TEV-56286
Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Actual
Start
Mar 10, 2025
Primary completion
May 22, 2025
Study completion Jun 2, 2025
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLCTeva (TEVA)
- Sponsor type
- Industry
- First posted
- Apr 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the study is to assess the relative bioavailability of TEV-56286 test formulations compared to TEV-56286 reference product in healthy adult participants. The secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned duration for each participant is approximately 70 days which includes a 45 day screening period.
Conditions
- Healthy Participants
Interventions
TEV-56286 TestDrug
Administered orally
TEV-56286 ReferenceDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Drug Concentration (Cmax)Time frame: Up to Day 17
- Area Under the Drug Concentration-Time Curve from Time 0 to Last Measurable Drug Concentration [AUC(0-t)]Time frame: Up to Day 17
- Area Under the Drug Concentration-Time Curve from Time 0 to Infinity [AUC(0-inf)]Time frame: Up to Day 17
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Teva Investigational Site 12141
Miramar, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.